消化

订阅

MedSci主页 / 所有栏目 / 消化

2019年ADA：口服semaglutide治疗2型糖尿病的心血管安全性可控

2019-06-12 不详 网络

semaglutide2型糖尿病MACE
关注

诺和诺德公司近日宣布，PIONEER 6试验通过比较口服semaglutide（胰高血糖素样肽-1类似物）与安慰剂，基于137个首次主要不良心血管事件和16个月的中位随访，证明了semaglutide的主要不良心血管事件（MACE）的非劣性。

诺和诺德公司近日宣布，PIONEER 6试验通过比较口服semaglutide（胰高血糖素样肽-1类似物）与安慰剂，基于137个首次主要不良心血管事件和16个月的中位随访，证明了semaglutide的主要不良心血管事件（MACE）的非劣性。PIONEER 6试验的主要终点为首次发生心血管死亡、非致命性心肌梗死或非致命性卒中的MACE复合结果。

PIONEER 6试验的主要结果将在2019年美国糖尿病协会（ADA）会议上发表，并同时发表在新英格兰医学杂志（NEJM）上。


原始出处：

http://www.firstwordpharma.com/node/1646837#axzz5qOw0cfEI

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078559, encodeId=edb420e855902, content=<a href='/topic/show?id=6c5951e9161' target=_blank style='color:#2F92EE;'>#心血管安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51791, encryptionId=6c5951e9161, topicName=心血管安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Sep 30 12:58:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947986, encodeId=327d194e98653, content=<a href='/topic/show?id=c81f51e92a5' target=_blank style='color:#2F92EE;'>#心血管安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51792, encryptionId=c81f51e92a5, topicName=心血管安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Fri Mar 20 20:58:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633176, encodeId=37da16331e6ae, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Mon Dec 09 02:58:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264715, encodeId=bdbe1264e158d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317513, encodeId=7c12131e51330, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042514, encodeId=8b1410425147b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 12 18:58:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-09-30 朱睿睿

    #心血管安全#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2078559, encodeId=edb420e855902, content=<a href='/topic/show?id=6c5951e9161' target=_blank style='color:#2F92EE;'>#心血管安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51791, encryptionId=6c5951e9161, topicName=心血管安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Sep 30 12:58:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947986, encodeId=327d194e98653, content=<a href='/topic/show?id=c81f51e92a5' target=_blank style='color:#2F92EE;'>#心血管安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51792, encryptionId=c81f51e92a5, topicName=心血管安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Fri Mar 20 20:58:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633176, encodeId=37da16331e6ae, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Mon Dec 09 02:58:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264715, encodeId=bdbe1264e158d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317513, encodeId=7c12131e51330, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042514, encodeId=8b1410425147b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 12 18:58:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2020-03-20 12498cf9m35(暂无昵称)

    #心血管安全性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2078559, encodeId=edb420e855902, content=<a href='/topic/show?id=6c5951e9161' target=_blank style='color:#2F92EE;'>#心血管安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51791, encryptionId=6c5951e9161, topicName=心血管安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Sep 30 12:58:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947986, encodeId=327d194e98653, content=<a href='/topic/show?id=c81f51e92a5' target=_blank style='color:#2F92EE;'>#心血管安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51792, encryptionId=c81f51e92a5, topicName=心血管安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Fri Mar 20 20:58:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633176, encodeId=37da16331e6ae, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Mon Dec 09 02:58:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264715, encodeId=bdbe1264e158d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317513, encodeId=7c12131e51330, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042514, encodeId=8b1410425147b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 12 18:58:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-12-09 lfyang

    #semaglutide#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2078559, encodeId=edb420e855902, content=<a href='/topic/show?id=6c5951e9161' target=_blank style='color:#2F92EE;'>#心血管安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51791, encryptionId=6c5951e9161, topicName=心血管安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Sep 30 12:58:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947986, encodeId=327d194e98653, content=<a href='/topic/show?id=c81f51e92a5' target=_blank style='color:#2F92EE;'>#心血管安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51792, encryptionId=c81f51e92a5, topicName=心血管安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Fri Mar 20 20:58:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633176, encodeId=37da16331e6ae, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Mon Dec 09 02:58:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264715, encodeId=bdbe1264e158d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317513, encodeId=7c12131e51330, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042514, encodeId=8b1410425147b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 12 18:58:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-14 般若傻瓜

    #ADA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2078559, encodeId=edb420e855902, content=<a href='/topic/show?id=6c5951e9161' target=_blank style='color:#2F92EE;'>#心血管安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51791, encryptionId=6c5951e9161, topicName=心血管安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Sep 30 12:58:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947986, encodeId=327d194e98653, content=<a href='/topic/show?id=c81f51e92a5' target=_blank style='color:#2F92EE;'>#心血管安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51792, encryptionId=c81f51e92a5, topicName=心血管安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Fri Mar 20 20:58:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633176, encodeId=37da16331e6ae, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Mon Dec 09 02:58:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264715, encodeId=bdbe1264e158d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317513, encodeId=7c12131e51330, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042514, encodeId=8b1410425147b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 12 18:58:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-14 fengyi812

    #EMA#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2078559, encodeId=edb420e855902, content=<a href='/topic/show?id=6c5951e9161' target=_blank style='color:#2F92EE;'>#心血管安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51791, encryptionId=6c5951e9161, topicName=心血管安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Sep 30 12:58:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947986, encodeId=327d194e98653, content=<a href='/topic/show?id=c81f51e92a5' target=_blank style='color:#2F92EE;'>#心血管安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51792, encryptionId=c81f51e92a5, topicName=心血管安全性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d47b2500175, createdName=12498cf9m35(暂无昵称), createdTime=Fri Mar 20 20:58:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633176, encodeId=37da16331e6ae, content=<a href='/topic/show?id=db1c1612602' target=_blank style='color:#2F92EE;'>#semaglutide#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16126, encryptionId=db1c1612602, topicName=semaglutide)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=214a22029963, createdName=lfyang, createdTime=Mon Dec 09 02:58:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264715, encodeId=bdbe1264e158d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317513, encodeId=7c12131e51330, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Jun 14 06:58:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042514, encodeId=8b1410425147b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jun 12 18:58:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Lancet Diabetes Endocrinol：Semaglutide 用于II型糖尿病临床新进展

对于对二甲双胍或噻唑烷二酮类药物血糖控制效果不佳的II型糖尿病患者，每周一次的Semaglutide在血糖和体重控制方面均优于西他列汀，并且表现出良好的安全性

JAMA：Semaglutide在降糖及体重控制的效果优于西他列汀

研究认为，对于服用二甲双胍效果不佳的II型糖尿病患者，接受每天7或14 mg的Semaglutide治疗，在血糖以及体重控制方面的效果均优于西他列汀

NEJM：Semaglutide不会威胁2型糖尿病患者的心血管安全性

对于2型糖尿病，指南规定新的糖尿病疗法要建立心血管安全性，以排除多余的心血管风险。semaglutide（胰高血糖素样肽1类似物，半衰期延长约1周）对于2型糖尿病患者的心血管作用还是未知的。原始出处：Steven P. Marso,Stephen C. Bain,Agostino Consoli,et al.Semaglutide and Cardiovascular Outcomes in Pa

EASD 2016：诺和诺德semaglutide使高危2型糖尿病患者主要心血管事件风险显著降低26%

糖尿病巨头诺和诺德（Novo Nordisk）近日在德国慕尼黑举行的第52届欧洲糖尿病研究协会（EASD）上公布了该公司正在开发的一款糖尿病新药semaglutide（索马鲁肽）一项III期临床研究（SUSTAIN 6）的新数据。 semaglutide是一种新型长效胰高血糖素样肽-1（GLP-1）类似物，每周皮下注射一次，可使2型糖尿病患者血糖水平大幅改善，并且低血糖风险较低。于此同时，sem

EASD 2016：诺和诺德长效GLP-1降糖药semaglutide三大功效：降糖，减肥，降低心血管风险

糖尿病巨头诺和诺德（Novo Nordisk）近日在德国慕尼黑举行的第52届欧洲糖尿病研究协会（EASD）上公布了该公司正在开发的一款糖尿病新药semaglutide（索马鲁肽）一项III期临床研究（SUSTAIN 5）的新数据。 semaglutide是一种新型长效胰高血糖素样肽-1（GLP-1）类似物，每周皮下注射一次，可使2型糖尿病患者血糖水平大幅改善，并且低血糖风险较低。于此同时，s

Lancet Diabetes Endocrinol：GLP类似物Semaglutide比甘精胰岛素疗法更具优势

GLP类似物Semaglutide对二甲双胍效果不佳的II型糖尿病患者比甘精胰岛素疗法更具优势